

# Missing Full Disclosures

*Neurol Neuroimmunol Neuroinflamm* 2025;12:e200342. doi:10.1212/NXI.000000000200342

For papers published in volume 10, issues 4–6, and volume 11, issue 1, full disclosures were missing online. The affected papers are listed below. This was a result of an error during migration to the current submissions platform. The editorial office regrets the absence of the full disclosures, which are now restored.

- “Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies” by Serrano-Castro et al.<sup>1</sup>
- “EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls” by Monaco et al.<sup>2</sup>
- “Frequency and Referral Patterns of Neural Antibody Studies During the COVID-19 Pandemic: Experience From an Autoimmune Neurology Center” by Ariño et al.<sup>3</sup>
- “IgG1-3 MuSK Antibodies Inhibit AChR Cluster Formation, Restored by SHP2 Inhibitor, Despite Normal MuSK, DOK7, or AChR Subunit Phosphorylation” by Cao et al.<sup>4</sup>
- “Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease” by Nguyen et al.<sup>5</sup>
- “LGI1 Encephalitis and IgG4-Related Disease: Rare Conditions Collide” by Jesuthasan et al.<sup>6</sup>
- “Mimics of Autoimmune Encephalitis: Validation of the 2016 Clinical Autoimmune Encephalitis Criteria” by Van Steenhoven et al.<sup>7</sup>
- “Prevalence, Clinical Profiles, and Prognosis of Stiff-Person Syndrome in a Japanese Nationwide Survey” by Matsui et al.<sup>8</sup>
- “Severe Neuroinvasive West Nile Virus in Association With Anti-CD20 Monotherapy for Multiple Sclerosis” by Thebault et al.<sup>9</sup>
- “Structural Changes of Cutaneous Immune Cells in Patients With Type 1 Diabetes and Their Relationship With Diabetic Polyneuropathy” by Hu et al.<sup>10</sup>
- “Subacute Horizontal Diplopia, Jaw Dystonia, and Laryngospasm” Tisavipat et al.<sup>11</sup>
- “Visual System Involvement in Glial Fibrillary Acidic Protein Astrocytopathy: Two Case Reports and a Systematic Literature Review” by Greco et al.<sup>12</sup>

## References

1. Serrano-Castro PJ, Rodríguez-Uranga JJ, Cabezudo-García P, et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(6):e200151. doi:10.1212/nxi.000000000200151
2. Monaco MC, Soldan SS, Su C, et al. EBNA1 inhibitors block proliferation of spontaneous lymphoblastoid cell lines from patients with multiple sclerosis and healthy controls. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(5):e200149. doi:10.1212/nxi.000000000200149
3. Ariño H, Ruiz García R, Rioseras B, et al. Frequency and referral patterns of neural antibody studies during the COVID-19 pandemic: experience from an autoimmune neurology center. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(4):e200129. doi:10.1212/nxi.000000000200129
4. Cao M, Liu WW, Maxwell S, et al. IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(6):e200147. doi:10.1212/nxi.000000000200147
5. Nguyen L, Miles DK, Harder L, et al. Increased intracranial pressure in pediatric myelin oligodendrocyte glycoprotein antibody–associated disease. *Neurol Neuroimmunol Neuroinflamm*. 2023;11(1):e200174. doi:10.1212/nxi.000000000200174
6. Jesuthasan A, Barwick T, Dixon L, et al. LGI1 encephalitis and igg4-related disease: rare conditions collide. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(6):e200158. doi:10.1212/nxi.000000000200158
7. Van Steenhoven RW, de Vries JM, Bruijstens AL, et al. Mimics of autoimmune encephalitis: validation of the 2016 clinical autoimmune encephalitis Criteria. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(6):e200148. doi:10.1212/nxi.000000000200148
8. Matsui N, Tanaka K, Ishida M, et al. Prevalence, clinical profiles, and prognosis of stiff-person syndrome in a Japanese nationwide survey. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(6):e200165. doi:10.1212/nxi.000000000200165
9. Thebault S, Gandelman S, Lane C, et al. Severe neuroinvasive West Nile virus in association with anti-CD20 monotherapy for multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(5):e200154. doi:10.1212/NXI.000000000200154
10. Hu X, Buhl CS, Sjøgaard MB, et al. Structural changes of cutaneous immune cells in patients with type 1 diabetes and their relationship with diabetic polyneuropathy. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(5):e200144. doi:10.1212/NXI.000000000200144
11. Tisavipat N, Chang BK, Ali F, et al. Subacute horizontal diplopia, jaw dystonia, and laryngospasm. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(4):e200128. doi:10.1212/nxi.000000000200128
12. Greco G, Masciochi S, Diamanti L, et al. Visual system involvement in glial fibrillary acidic protein astrocytopathy: two case reports and a systematic literature review. *Neurol Neuroimmunol Neuroinflamm*. 2023;10(5):e200146. doi:10.1212/nxi.000000000200146